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The authors decided to evaluate the possible use of methyl-aminolevulinate photodynamic therapy 
(MAL-PDT) as adjunctive therapy for morpheaform basal cell carcinoma prior to standard surgical 
excision in order to reduce tumor size and volume and to facilitate surgical treatment. It was obser-
ved that MAL-PDT may be an option as an adjunctive therapy prior to standard surgical excision of 
morpheaform basal cell carcinoma, leading to less invasive surgery.
S U M M A R Y
Topical photodynamic therapy has demonstrated 
KLJKHIÀFDF\ LQ WKH WUHDWPHQWRIQRQPHODQRPDVNLQ
cancers such as actinic keratoses, Bowen’s disease, 
DQGEDVDOFHOOFDUFLQRPDVXSHUÀFLDODQGQRGXODU%H-
cause of its excellent cosmetic results it has also been 
XVHGZLWKJRRGUHVXOWVLQ´GLIÀFXOWWRWUHDWµEDVDOFHOO
carcinomas (large lesions, multifocal, or mid-facially 
ORFDOL]HGOHVLRQVWKDWZRXOGRWKHUZLVHUHTXLUHH[WHQ-
sive surgical procedures (1). Morpheaform basal cell 
carcinoma is a rare variant in which tumor cells induce 
DSUROLIHUDWLRQRIÀEUREODVWVZLWKLQWKHGHUPLVDQGDQ
increased collagen deposition that clinically resembles 
D VFDU%HFDXVH WKH WXPRU LQÀOWUDWHV LQ WKLQ VWUDQGV
EHWZHHQFROODJHQÀEHUVWUHDWPHQWLVGLIÀFXOWDQGWKH
FOLQLFDOPDUJLQV DUHGLIÀFXOW WRGLVWLQJXLVK6XUJHU\
particularly Mohs surgery, is the treatment of choice 
for this type of basal cell carcinoma.
The authors decided to evaluate the possible use 
of methyl-aminolevulinate photodynamic therapy 
(MAL-PDT) as an adjunctive therapy for morphea-
form basal cell carcinoma prior to standard surgical 
excision (Mohs surgery is not available at our center) 
LQRUGHUWRUHGXFHWXPRUVL]HDQGYROXPHDQGIDFLOL-
tate surgical treatment. Therefore, the aim was to as-
sess if this approach could lead to less invasive sur-
gery, which can be particularly relevant in the excision 
of basal cell carcinomas on the face.
6L[ KLVWRORJLFDOO\ FRQÀUPHG PRUSKHDIRUP EDVDO
cell carcinomas were carefully selected (Fig. 1). Three 
tumors were located on the face and three on the 
back. The lesion dimensions (clinical dimensions) and 
location are shown in Table 1. Two treatments with 
0$/3'7ZHHNDSDUWZHUHSHUIRUPHGDQDSSOLFD-
tion of approximately 1 mm thick of 160 mg/g MAL 
cream (Metvix®, Galderma, France) was applied 
on the lesion and 5 to 10 mm of surrounding skin. 
The lesion was then covered by an adhesive, occlu-
sive dressing for 3 hours, after which time the cream 
was removed by rinsing with saline solution. The le-
sion was immediately illuminated with an LED light 
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source (Aktilite® CL16 & CL128 lamps, PhotoCure 
ASA, Norway) which emits red light at an average 
wavelength of approximately 630 nm at a dosage of 37 
J/cm². The patients were examined to assess the clini-
cal response 3 weeks after the two treatments with 
0$/3'7DQGWKHFOLQLFDOVL]HRIDOOWKHWXPRUVZDV
VLJQLÀFDQWO\UHGXFHG²7KHVXUJLFDOH[FLVLRQV
performed (traditional surgery, because Mohs surgery 
is not available at our center) with 5 mm margins were 
less extensive that those that would have been neces-
VDU\ LQLWLDOO\ EHFDXVH WKH FOLQLFDO VL]HV RI DOO WXPRUV
ZHUHVLJQLÀFDQWO\UHGXFHG+LVWRSDWKRORJLFDOO\DOOWKH
excision margins were tumor-free. After 2½ years, all 
the patients remained without any evidence of recur-
rence and the cosmetic outcome was considered very 
good (Fig. 2).
Combining more than one therapeutic modality 
has the potential advantage of enhancing the cure 
UDWHZKLOHPLQLPL]LQJDGYHUVHHIIHFWV DQGPD[LPL]-
ing cosmetic results. The use of an adjunctive therapy 
prior to surgical treatment may allow a reduction in 
tumor volume along with the possible induction of an 
immune response to the tumor, facilitating excision 
RIWKHFDQFHU7RSLFDOÁXRURXUDFLOFUHDPRU
imiquimod cream has been used to pretreat basal cell 
carcinoma prior to surgery, leading to a decrease in 
WKHHYHQWXDOZRXQGVL]H&RPELQDWLRQWKHUDS\
with methyl-aminolevulinate photodynamic therapy 
(MAL-PDT) and imiquimod cream has also been 
reported in the treatment of nodular basal cell carci-
noma (5).
Important limitations of this study obviously in-
clude the small number of patients and the fact that 
ÁXRUHVFHQFHVWXGLHVZHUHQRWSHUIRUPHGIROORZLQJWKH
MAL application, which could have offered additional 
SURRIRIWKHEHQHÀFLDOHIIHFWRIWKH0$/3'7
Although no reports can be found in the literature 
concerning the use of topical photodynamic therapy 
in the treatment of morpheaform basal cell carcinoma, 
and despite the small number of patients taken into 
consideration, this preliminary study has found that 
MAL-PDT may be an option as an adjunctive therapy 
prior to standard surgical excision of morpheaform 
basal cell carcinoma, especially when Mohs surgery is 
not available. Further studies and longer clinical fol-
ORZXSVDUHQHFHVVDU\WRFRQÀUPRXUÀQGLQJV
Figure 1. Histopathological examination  
(H&E, 4×).
Figure 2. Clinical features of the lesion before 
treatment (a); 3 weeks after two treatments with 
MAL-PDT 1 week apart (b); 18-month follow-up 
after PDT and surgical excision (c and d).
Table 1. Lesion location and clinical dimensions.
Case Location Clinical size 
1 Face (malar) 2.7 cm × 1.6 cm
2 Face (mandibular) 2.5 cm × 1.3 cm
3 Face (cheek) 2.0 cm × 0.9 cm
4 Dorsum 3.7 cm × 2.3 cm
5 Dorsum 2.9 cm × 1.9 cm
6 Presternal 3.5 cm × 1.7 cm
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